Business Standard

Dishman Pharma hits new high; stock surges over 35% in two days

In past two trading days, the stock zoomed 39% from Rs 232 to Rs 322 on BSE on back of heavy volumes

Pharma
Premium

SI Reporter Mumbai
Dishman Pharmaceuticals and Chemicals hit a fresh record high of Rs 322, up 16% on BSE on back of heavy volumes after the company on Tuesday said that its partner Tesaro Inc received US Food and Drug Administration (FDA) nod for cancer drug Zejula capsules.

The stock of drug maker has rallied 39% in past two trading sessions from Rs 232 on March 27, 2017.

“We believe that the increase in the stock price is based upon market estimation that we are one of the suppliers of the API for "Zejula" capsules, which got approved by the US

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in